ACA heads into the back half of the year with a strong price run behind it and the first signs of a quieter, more measured options market emerging from an unusually defensive stretch.
The most interesting tension this week is in options, and it tells a constructive story with a caveat. The put/call ratio has dropped sharply to 1.62, down from readings consistently above 4.5 through most of August and as high as 4.82 on August 14. That was an extreme level of downside protection by any measure. The retreat to 1.62 — still above the 20-day mean of 3.06, but now running more than one standard deviation below it — signals that the hedging pressure which dominated most of August is unwinding quickly. The stock gained 12% in the past week and is up nearly 16% over the past month to close at $145.45, so the options shift appears to track a genuine re-rating rather than simply a mechanical roll of protection.
The lending market offers no friction for would-be bears. Short interest is a modest 1.7% of the free float — low enough that it barely registers as a contrarian signal — and has been falling steadily all month, down about 3.2% over the past week and nearly 17% over 30 days. Borrow costs are negligible at 0.45%, with availability running at roughly 4,600% — meaning there are many times more shares available to borrow than are currently shorted. Nothing in the lending market suggests a coordinated bearish position is building. The ORTEX short score of 28.8 confirms this: it has barely moved in two weeks and ranks in the 80th percentile for lowest short conviction.
The Street's formal coverage is thin but leaning positive. The two analysts covering ACA hold a consensus "hold," but the most recent moves tell a different story directionally. Oppenheimer assumed coverage in late May with an Outperform and a $150 target. Barclays raised its target from $115 to $140 in early May, maintaining Overweight. DA Davidson has a Buy with a $125 target from March — now well below where the stock is trading, suggesting that number is due for a refresh. The mean target of roughly $147 is essentially in line with the current price, so the Street is not broadly flagging further upside from here, even if individual analysts remain bullish on the thesis. Bulls point to Arcosa's growing aggregates and infrastructure mix, with the Construction Products segment targeting around 65% of EBITDA and segment margins already running above 26%. Bears cite exposure to federal infrastructure funding timelines and commodity cost volatility.
Institutional ownership adds a supportive backdrop. BlackRock has been building — its most recent reported position of 17.1% of shares is the largest single block, and it added roughly 795,000 shares in the most recently disclosed period. State Street added about 98,000 shares. Balyasny and Pentwater, both active managers, each initiated positions during Q2. That cluster of fresh institutional interest is notable for a mid-cap construction and engineering name. On the insider side, a wave of gift-coded transactions (code G) filed in late August — from the CEO, CFO, CLO, and others — carry no read-through on sentiment. They are routine compensation-related transfers, not open-market signals.
The next earnings event is scheduled for late October. With peers FIX up 6% on the week and ECG up 1.3%, the broader infrastructure group is in a constructive phase. The question heading into October's print is whether the recent margin story — and the guidance raise noted from Q2 — holds as the calendar turns into a seasonally softer period for construction activity.
See the live data behind this article on ORTEX.
Open ACA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
